Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
NCT ID: NCT03141918
Last Updated: 2018-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2017-09-08
2017-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients
NCT03470376
Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS
NCT02180035
Botanical/Drug Interactions in HIV: Glucuronidation
NCT00065741
The Impact of Oral Health in HIV Patients on Antiretroviral Therapy
NCT04645693
Metformin for HIV Inflammation
NCT02383563
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The sample will consist of 20 volunteers, 10 in the experimental group (GE) and 10 in the control group (CG). Participants will be randomly assigned to one of the groups by lottery by a researcher not participating in the study. The researcher responsible, as well as the volunteers, will not be aware of which participants are in the GE or the GC.
The study will be carried out in the Movement Laboratory of the Physical Education Department of the Federal University of Rio Grande do Norte.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Curcumin group 1
Intervention will be with intake of curcumin, 1000mg per 30 days
Curcumin
The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
Curcumin group 2
Intervention will be with placebo intake of curcumin, 1000mg per 30 days
Placebo of Curcumin
The intervention will consist of the placebo administration curcumin for 30 days.
The Curcumin placebo will be given in 2 doses of 500mg per day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Curcumin
The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
Placebo of Curcumin
The intervention will consist of the placebo administration curcumin for 30 days.
The Curcumin placebo will be given in 2 doses of 500mg per day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidade Federal do Rio Grande do Norte
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
TATIANE ANDREZA LIMA DA SILVA
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
TATIANE AL SILVA, Ms
Role: PRINCIPAL_INVESTIGATOR
UFRN - Avenida Salgado Filho. S/N. Campus Central. Lagoa Nova. Rio Grande do Norte, Brazil
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universidade Federal Do Rio Grande Do Norte
Natal, Rio Grande do Norte, Brazil
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pannacciulli N, Salbe AD, Ortega E, Venti CA, Bogardus C, Krakoff J. The 24-h carbohydrate oxidation rate in a human respiratory chamber predicts ad libitum food intake. Am J Clin Nutr. 2007 Sep;86(3):625-32. doi: 10.1093/ajcn/86.3.625.
Kosmiski LA, Bessesen DH, Stotz SA, Koeppe JR, Horton TJ. Short-term energy restriction reduces resting energy expenditure in patients with HIV lipodystrophy and hypermetabolism. Metabolism. 2007 Feb;56(2):289-95. doi: 10.1016/j.metabol.2006.10.012.
Vassimon HS, de Paula FJ, Machado AA, Monteiro JP, Jordao AA Jr. Hypermetabolism and altered substrate oxidation in HIV-infected patients with lipodystrophy. Nutrition. 2012 Sep;28(9):912-6. doi: 10.1016/j.nut.2011.12.010. Epub 2012 Apr 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COMPOSTOS_BIOATIVOS_VIVER MAIS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.